Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · April 20, 2024

Predictors for Improvement in Patient-Reported Outcomes in Complement Inhibitor–Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab and Ravulizumab

Annals of Hematology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Hematology
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
Ann Hematol 2024 Jan 01;103(1)5-15, H Schrezenmeier, A Kulasekararaj, L Mitchell, RP de Latour, T Devos, S Okamoto, R Wells, E Popoff, A Cheung, A Wang, I Tomazos, Y Patel, JW Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading